Fludarabine
Multi-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of MedicineSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Multi-Drug Resistant Nephrotic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ucar T-Cell The Children's Hospital of Zhejiang University School of Medicine | Phase 1 | CCC |
Cyclophosphamide The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
RD06-05 CART Cell The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
qt-219cx The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →